Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss
Mahmoud H. Elbatreek, Zhen Li, Xiaoman Yu…·David J. Lefer
This study shows low-dose GLP-1RA therapy improves cardiac and hepatic function in HFpEF without weight loss, through mechanisms like reduced fibrosis and lipid accumulation.